|
|
|
|
|
|
Evaluation of Selling Direct Versus Out-Licensing: The Health Advances team outlined the risks, costs, and likely success of marketing a novel oncology agent to an early stage biotech company alone versus
the likely outcomes if that agent were licensed out to a large pharmaceutical company. This was the second phase of a two-phase project. In the first phase, Health
Advances evaluated the market potential for this novel agent in its main indications, CLL and NHL..
Assessment of Key Commercialization Strategic Options for a Novel Therapeutic: Health Advances developed the US commercialization plan for a novel therapeutic
targeted towards dermatologists and endocrinologists. The plan outlined the impact on top-line sales of marketing this drug alone or with a partner and the estimated expense
requirements. Based on Health Advances' analysis, the company decided to actively pursue a co-development partnership and used this work to negotiate terms with the company.
Development of a US Marketing Strategy: A Health Advances team assisted with the development of the US marketing strategy for a large pharmaceutical company,
including recommendations for budget allocations across sales and marketing activities. The work required a detailed review of salesforce , marketing and Phase IV clinical
trial strategies.
Evaluation of a Product Launch Tool: Health Advances evaluated the role of medical education in new product launches. The team profiled the average spent on medical
education relative to top-line sales and other marketing activities as a part of this analysis.
|
|
 |
|
|
|
|
